STAT1d
Pharmalittle: We’re reading about a pharma tariff exception, FDA inspection cutbacks, and more
The Trump administration carved out an exception for pharmaceuticals from the president's new tariff regime, at least for now ...
Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...
Fierce Pharma4d
Judge levies $1.64B penalty on Johnson & Johnson in HIV drug marketing case
Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...
Becker's Hospital Review3d
J&J hit with $1.64B penalty for illegal drug marketing practices
A federal judge has ordered Johnson & Johnson’s Janssen unit to pay $1.64 billion for illegally promoting HIV drugs Prezista ...
Medscape11d
FDA OKs Guselkumab for Crohn’s Disease
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a ...
Johnson & Johnson’s $55 billion US commitment begins with Eastern NC plant groundbreaking
Executives mingled with North Carolina leaders in the city of Wilson to ceremonially break ground on Johnson & Johnson’s ...
Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)
Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...
J&J unit ordered to pay $1.64B in HIV drug marketing case, Reuters reports
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64B after a jury found it liable in a ...